IS2661B - Lyfjablanda sem samanstendur af hindra fyrir proteinkljúfandi hvata og monoglycerid - Google Patents

Lyfjablanda sem samanstendur af hindra fyrir proteinkljúfandi hvata og monoglycerid

Info

Publication number
IS2661B
IS2661B IS4627A IS4627A IS2661B IS 2661 B IS2661 B IS 2661B IS 4627 A IS4627 A IS 4627A IS 4627 A IS4627 A IS 4627A IS 2661 B IS2661 B IS 2661B
Authority
IS
Iceland
Prior art keywords
inhibitors
monoglyceride
proteolytic
catalysts
pharmaceutical composition
Prior art date
Application number
IS4627A
Other languages
English (en)
Icelandic (is)
Other versions
IS4627A (is
Inventor
Carole Anne Bailey
Christine Josephine Ferdinando
Navnit Shah
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/616,233 external-priority patent/US6008228A/en
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of IS4627A publication Critical patent/IS4627A/is
Publication of IS2661B publication Critical patent/IS2661B/is

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/472Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4858Organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4866Organic macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
IS4627A 1995-06-06 1997-12-04 Lyfjablanda sem samanstendur af hindra fyrir proteinkljúfandi hvata og monoglycerid IS2661B (is)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US46849395A 1995-06-06 1995-06-06
US08/616,233 US6008228A (en) 1995-06-06 1996-05-07 Pharmaceutical compositions containing proteinase inhibitors
PCT/EP1996/002431 WO1996039142A1 (fr) 1995-06-06 1996-06-04 Compositions pharmaceutiques comprenant un inhibiteur de proteinases et un monoglyceride

Publications (2)

Publication Number Publication Date
IS4627A IS4627A (is) 1997-12-04
IS2661B true IS2661B (is) 2010-08-15

Family

ID=27042422

Family Applications (1)

Application Number Title Priority Date Filing Date
IS4627A IS2661B (is) 1995-06-06 1997-12-04 Lyfjablanda sem samanstendur af hindra fyrir proteinkljúfandi hvata og monoglycerid

Country Status (27)

Country Link
EP (1) EP0831826B1 (fr)
JP (1) JP3238412B2 (fr)
CN (1) CN1092960C (fr)
AT (1) ATE226075T1 (fr)
AU (1) AU709796B2 (fr)
BG (1) BG63711B1 (fr)
BR (1) BR9610842A (fr)
CA (1) CA2224125C (fr)
CY (1) CY2373B1 (fr)
CZ (1) CZ292192B6 (fr)
DE (1) DE69624354T2 (fr)
DK (1) DK0831826T3 (fr)
EA (1) EA001413B1 (fr)
ES (1) ES2182996T3 (fr)
HK (1) HK1010136A1 (fr)
HU (1) HU223899B1 (fr)
IL (1) IL122353A0 (fr)
IS (1) IS2661B (fr)
MX (1) MX9709193A (fr)
NO (1) NO324531B1 (fr)
NZ (1) NZ311646A (fr)
OA (1) OA10546A (fr)
PL (1) PL184820B1 (fr)
PT (1) PT831826E (fr)
SK (1) SK282121B6 (fr)
TR (1) TR199701541T1 (fr)
WO (1) WO1996039142A1 (fr)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0989851T3 (da) 1997-07-29 2003-01-27 Upjohn Co Selvemulgerende formulering indeholdende sure lipofile forbindelser
CN1113650C (zh) 1997-07-29 2003-07-09 法玛西雅厄普约翰美国公司 自体乳化剂形式的亲脂性化合物的药物组合物
US7258869B1 (en) 1999-02-08 2007-08-21 Alza Corporation Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicle
US7919109B2 (en) 1999-02-08 2011-04-05 Intarcia Therapeutics, Inc. Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicles
CN1232244C (zh) * 1999-02-08 2005-12-21 阿尔萨公司 稳定的非水性单相粘性载体及采用该载体的制剂
US6956048B2 (en) 1999-03-31 2005-10-18 Pharmacia & Upjohn Company Pharmaceutical emulsions for retroviral protease inhibitors
US6309663B1 (en) * 1999-08-17 2001-10-30 Lipocine Inc. Triglyceride-free compositions and methods for enhanced absorption of hydrophilic therapeutic agents
BR0202252A (pt) 2002-06-12 2004-06-29 Cristalia Prod Quimicos Farm Composição farmacêutica solúvel estável para administração de inibidores da hiv protease e processo de obtenção de composições farmacêuticas concentradas para a administração de inibidores da hiv protease
US7731947B2 (en) 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
WO2006083761A2 (fr) 2005-02-03 2006-08-10 Alza Corporation Solutions de solvant/polymere utilisees comme vehicules de suspension
KR101106510B1 (ko) 2006-05-30 2012-01-20 인타르시아 세라퓨틱스 인코포레이티드 투피스, 내부채널 삼투압 전달 시스템 유동 조절기
ES2402172T3 (es) 2007-04-23 2013-04-29 Intarcia Therapeutics, Inc Formulación en suspensión de péptidos insulinotrópicos y usos de los mismos
EP2240155B1 (fr) 2008-02-13 2012-06-06 Intarcia Therapeutics, Inc Dispositifs, formulations et méthodes d administration de plusieurs agents bénéfiques
EP2108705A1 (fr) 2008-04-08 2009-10-14 Universität Duisburg-Essen Procédé d'analyse de l'état épigénétique du gène HtrA 1
CN107638562B (zh) 2009-09-28 2022-12-02 精达制药公司 基本稳态药物递送的快速建立和/或终止
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
US10925639B2 (en) 2015-06-03 2021-02-23 Intarcia Therapeutics, Inc. Implant placement and removal systems
BR112018073511A2 (pt) 2016-05-16 2019-03-26 Intarcia Therapeutics, Inc. polipeptídeos seletivos do receptor de glucagon e métodos de uso dos mesmos
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
MX2019008006A (es) 2017-01-03 2019-08-29 Intarcia Therapeutics Inc Metodos que comprenden la administracion continua de un agonista del receptor de glp-1 y la co-administracion de un farmaco.

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8927913D0 (en) * 1989-12-11 1990-02-14 Hoffmann La Roche Amino acid derivatives
IL110752A (en) * 1993-09-13 2000-07-26 Abbott Lab Liquid semi-solid or solid pharmaceutical composition for an HIV protease inhibitor

Also Published As

Publication number Publication date
AU709796B2 (en) 1999-09-09
IL122353A0 (en) 1998-04-05
DK0831826T3 (da) 2003-02-03
JP3238412B2 (ja) 2001-12-17
OA10546A (en) 2002-05-29
NO975665L (no) 1998-02-05
EP0831826A1 (fr) 1998-04-01
JPH10507202A (ja) 1998-07-14
SK162797A3 (en) 1998-05-06
NZ311646A (en) 2000-02-28
IS4627A (is) 1997-12-04
TR199701541T1 (xx) 1998-03-21
EA001413B1 (ru) 2001-02-26
PL184820B1 (pl) 2002-12-31
SK282121B6 (sk) 2001-11-06
PT831826E (pt) 2003-02-28
HU223899B1 (hu) 2005-03-29
AU6300496A (en) 1996-12-24
CZ292192B6 (cs) 2003-08-13
EP0831826B1 (fr) 2002-10-16
PL323860A1 (en) 1998-04-27
BG102106A (en) 1998-08-31
HK1010136A1 (en) 1999-06-17
DE69624354D1 (de) 2002-11-21
MX9709193A (es) 1998-03-31
CN1186434A (zh) 1998-07-01
CY2373B1 (en) 2004-06-04
BG63711B1 (bg) 2002-10-31
DE69624354T2 (de) 2003-06-05
CA2224125A1 (fr) 1996-12-12
WO1996039142A1 (fr) 1996-12-12
NO324531B1 (no) 2007-11-12
EA199800023A1 (ru) 1998-08-27
CZ380397A3 (cs) 1998-03-18
ES2182996T3 (es) 2003-03-16
NO975665D0 (no) 1997-12-05
ATE226075T1 (de) 2002-11-15
CN1092960C (zh) 2002-10-23
BR9610842A (pt) 1999-07-13
HUP9801905A2 (hu) 1999-05-28
HUP9801905A3 (en) 2001-04-28
CA2224125C (fr) 2004-09-28

Similar Documents

Publication Publication Date Title
IS2661B (is) Lyfjablanda sem samanstendur af hindra fyrir proteinkljúfandi hvata og monoglycerid
DK1915993T3 (da) Synergistiske kombinationer omfattende en renininhibitor til hjertekarsygdomme
ZA9811830B (en) Prodrugs of aspartyl protease inhibitors.
HUP0100669A3 (en) Peptide derivatives as serine protease inhibitors, their use and pharmaceutical compositions comprising thereof
HK1027748A1 (en) Use of 3-benzoyl-phenylacetic acids, esters, or amides for treatment of glcia glaucoma
MY116525A (en) Pharmaceutical composition comprising a proteinase inhibitor and a monoglyceride
HUP9900390A3 (en) Serine protease inhibitors, and pharmaceutical compositions containing them
HRP20030983B1 (en) Pharmaceutical composition comprising a lipase inhibitor and a sucrose fatty acid ester
IL122942A0 (en) Esters of 1-beta-d-arabinofuranosylcytosine and pharmaceutical compositions containing them
EP0983243A4 (fr) Nouveaux quinoline- et naphthalenecarboxamides, compositions pharmaceutiques et procedes d'inhibition de la calpaine